The BMS 2025 Protocol: Optimising Your HRT and Weight Loss Journey The British Menopause Society (BMS) updated its guidance in April 2026 to address the increasing use of GLP-1 receptor agonists among menopausal women
You shouldnt take tirzepatide medications or Wegovy if you have: A personal or family history of medullary thyroid carcinoma (MTC) A history of multiple endocrine neoplasia syndrome type 2 (MEN 2) A serious allergic reaction to tirzepatide, semaglutide , or any of the ingredients in these medications Your clinician will determine if GLP-1 medications are right for you if you have a history of: Pancreatitis , kidney problems, or gallbladder disease, including gallstones Diabetic retinopathy Gastroparesis or other serious digestive conditions Tirzepatide and Wegovy are also not for people who are pregnant, planning to become pregnant, or breastfeeding
Standard escalation protocol Most semaglutide research protocols follow a gradual escalation pattern designed to minimize gastrointestinal side effects like constipation , burping , and dizziness
I hope youre finding some peace among the chaos, and some normality among the abnormality
[11] More generally, improving glucose metabolism has been shown to slow, or even partially reverse, the cognitive decline associated with aging and dementia
A very high level of pairwise similarity is consistent with the relative ease with which inducer specificity can be relaxed or switched in an FrmR by simple reintroduction of the Z-position His residue found in RcnRs
